Aller directement au menu principal Aller directement au contenu principal Aller au pied de page
Cortica

Cortica explique-moi

Vol. 2 No. 2 (2023): OPEN SCIENCE : Accès aux savoirs scientifiques auprès des professionnels de santé et contribuer à la littératie scientifique citoyenne

Psychotropes

  • Madeleine Moix
  • Mathilde Thierrin
DOI
https://doi.org/10.26034/cortica.2023.4181
Soumise
August 28, 2023
Publié-e
2023-09-19

Résumé

Psychotropes

Références

  1. Cours de Dr. Cherine Fahmy "La psychopathologie et ses bases biologiques", au semestre de printemps 2023, à l'Université de Fribourg
  2. American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Washington, DC: American Psychiatric Association;1994
  3. Arnaout, B., & Petrakis, I. L. (2011). Sedative-Hypnotics and Anxiolytics. In B. A. Johnson (Ed.), Addiction Medicine: Science and Practice (pp. 511–523). Springer. https://doi.org/10.1007/978-1-4419-0338-9_23
  4. Bolstad, I., Alakokkare, A.-E., Bramness, J. G., Rognli, E. B., Levola, J., Mustonen, A., Miettunen, J., & Niemelä, S. (2022). The relationships between use of alcohol, tobacco and coffee in adolescence and mood disorders in adulthood. Acta Psychiatrica Scandinavica, 146(6), 594–603. https://doi.org/10.1111/acps.13506
  5. Carney, T., Wells, J., Parry, C. D. H., McGuinness, P., Harris, R., & Hout, M. C. V. (2018). A comparative analysis of pharmacists’ perspectives on codeine use and misuse – a three country survey. Substance Abuse Treatment, Prevention, and Policy, 13(1), 12. https://doi.org/10.1186/s13011-018-0149-2
  6. Crocq, M.-A. (2003). Alcohol, nicotine, caffeine, and mental disorders. Dialogues in Clinical Neuroscience, 5(2), 175–185. https://doi.org/10.31887/DCNS.2003.5.2/macrocq
  7. De Gregorio, D., Posa, L., Ochoa-Sanchez, R., McLaughlin, R., Maione, S., Comai, S., & Gobbi, G. (2016). The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors. Pharmacological Research, 113, 81‐91. https://doi.org/10.1016/j.phrs.2016.08.022
  8. Karila, L., Lafaye, G., Coscas, S., Blecha, L., & Benyamina, A. (2017). Le cannabis: Addiction. Conséquences aiguës et chroniques. Pratiques en santé mentale, 63, 15‐20. https://doi.org/10.3917/psm.172.0015
  9. Merikangas, K. R., & McClair, V. L. (2012). Epidemiology of substance use disorders. Human Genetics, 131(6), 779–789. https://doi.org/10.1007/s00439-012-1168-0
  10. Motaghinejad, M., Sadeghi-Hashjin, G., Koohi, M. K., & Karimian, S. M. (2016). Attenuation of withdrawal signs, blood cortisol, and glucose level with various dosage regimens of morphine after precipitated withdrawal syndrome in mice. Iranian Journal of Medical Sciences, 41(1), 53‐58.
  11. Nevid, J. S., Rathus, S., & Greene, B. (2009). Psychopathologie. Pearson Education France.
  12. Rhemtulla, M., Fried, E. I., Aggen, S. H., Tuerlinckx, F., Kendler, K. S., & Borsboom, D. (2016). Network analysis of substance abuse and dependence symptoms. Drug and Alcohol Dependence, 161, 230–237. https://doi.org/10.1016/j.drugalcdep.2016.02.005
  13. Schellhas, L., Haan, E., Easey, K. E., Wootton, R. E., Sallis, H. M., Sharp, G. C., Munafò, M. R., & Zuccolo, L. (2021). Maternal and child genetic liability for smoking and caffeine consumption and child mental health: An intergenerational genetic risk score analysis in the ALSPAC cohort. Addiction, 116(11), 3153–3166. https://doi.org/10.1111/add.15521
  14. Silva, L., & Bravo, L. (2022). Does LSD have any therapeutical value in mental disorders? A non-systemic review. European Psychiatry, 65(S1), S876-S876. doi:10.1192/j.eurpsy.2022.2272